AbbVie/Enanta HCV Regimen Posts Strong Data In First Of Six Phase III Trials
This article was originally published in The Pink Sheet Daily
Executive Summary
Three-drug combo posts high cure rates but analysts think pill burden may prove a significant disadvantage compared to Gilead’s regimen. Enanta is in place to earn royalties on AbbVie combo but also working with the pharma on a next-generation, two-drug combination for HCV.